Jefferies Initiates Dicerna Pharmaceuticals At Buy

Analysts at Jefferies initiated coverage on

with a Buy rating. The target price for Dicerna Pharmaceuticals is set to $25. Dicerna Pharmaceuticals shares have gained 1.79 percent over the past 52 weeks, while the S&P 500 index has surged 10.46 percent in the same period. Dicerna Pharmaceuticals' shares dropped 3.24 percent to close at $16.45 yesterday.